Press releases
5 November, 2026
Nanexa publishes interim report for July-September 2026
A strategically important third quarter for Nanexa, marked by an agreement with Novo and scientific and operational progress
Read more24 September, 2026
Nanexa and Novo enter into EUR 1.165 billion global license and collaboration agreement for long-acting injectables
• The agreement grants Novo a global exclusive license to Nanexa’s proprietary PharmaShell® atomic layer deposition (ALD) drug delivery technology platform for certain therapeutic peptide drugs in indications including obesity,
Read more22 September, 2026
Forge Nano and Nanexa Enter Joint Development Agreement to Advance Manufacturing for ALD-Coated PharmaShell® Long-Acting Injectable Medicines
Collaboration intended to develop large-scale, GMP-compliant ALD manufacturing equipment supporting Nanexa’s broad portfolio of proprietary and partnered PharmaShell® programs.
Read moreLatest reports
Presentations
5 November 2026
Q3 report commentary with CEO David Westberg and Chairman of the Board Göran Ando
25 September 2026
David Westberg and Göran Ando presents the Novo agreement with Q&A – Sept 25th
27 August 2026
Q2 report commentary with CEO David Westberg
18–20 May 2026